

ACELRX PHARMACEUTICALS INC
Form S-8
March 07, 2016

As filed with the Securities and Exchange Commission on March 7, 2016

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

ACELRX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

	351 Galveston Drive	
Delaware	Redwood City, CA 94063	41-2193603
	(650) 216-3500	
(State or other jurisdiction of incorporation or organization) including zip code)	(Address of principal executive offices, (I.R.S. Employer Identification No.)	

2011 Equity Incentive Plan

2011 Employee Stock Purchase Plan

(Full titles of the plans)

Howard B. Rosen

Interim Chief Executive Officer

AcelRx Pharmaceuticals, Inc.

351 Galveston Drive

Redwood City, CA 94063

(650) 216-3500

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Mark B. Weeks

Cooley LLP

3175 Hanover Street

Palo Alto, California 94304

(650) 843-5000

Facsimile: (650) 849-7400

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company)

reporting
company)

CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered	Amount to be Registered(1)	Proposed Maximum Offering Price Per Share(2)	Proposed Maximum Aggregate Offering Price(2)	Amount of Registration Fee
Common Stock, par value \$0.001 per share	2,714,859 shares	\$3.96	\$10,752,335	\$1,083

(1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the Registrant's Common Stock that become issuable under the plan set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of the Registrant's

Common Stock.

Estimated
solely for the
purpose of
calculating the
amount of the
registration fee
pursuant to
Rule 457(h) and
Rule 457(c)
promulgated
under the
Securities Act.

(2) The offering
price per share
and the
aggregate
offering price
are based upon
the average of
the high and
low prices of
the Registrant's
Common Stock
as reported on
the NASDAQ
Global Market
on March 4,
2016.

EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional (i) 1,809,906 shares of the common stock of AcelRx Pharmaceuticals, Inc. (the “Registrant”) to be issued pursuant to the Registrant’s 2011 Equity Incentive Plan and (ii) 904,953 shares of the Registrant’s common stock to be issued pursuant to the Registrant’s 2011 Employee Stock Purchase Plan.

INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8

The contents of the Registration Statements on Form S-8 (File Nos. 333-202709, 333-194634, 333-187206, 333-180334 and 333-172409) are incorporated by reference herein.

EXHIBITS

Exhibit Number	Description
3.1	Amended and Restated Certificate of Incorporation of the Registrant. ⁽¹⁾
3.2	Amended and Restated Bylaws of the Registrant. ⁽²⁾
4.1	Reference is made to Exhibits 3.1 and 3.2.
4.2	Specimen Common Stock Certificate of the Registrant. ⁽³⁾
4.3	Second Amended and Restated Investor’s Rights Agreement, among the Registrant and certain of its security holders, dated as of November 23, 2009. ⁽⁴⁾
4.4	Warrant to Purchase Common Stock of the Registrant, issued to Hercules Technology II, L.P., dated as of December 16, 2013. ⁽⁵⁾
4.5	Warrant to Purchase Common Stock of the Registrant, issued to Hercules Technology Growth Capital, Inc., dated as of December 16, 2013. ⁽⁶⁾
4.6	Form of Warrant issued to certain purchasers pursuant to the Securities Purchase Agreement dated May 29, 2012, between the Registrant and the purchasers identified therein. ⁽⁷⁾

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form S-8

- 4.7 Warrant Modification Agreement to Purchase Common Stock of the Registrant, issued to Hercules Technology II, L.P. dated as of September 17, 2015. ⁽⁸⁾
- 4.8 Warrant Modification Agreement to Purchase Common Stock of the Registrant, issued to Hercules Technology Growth Capital, Inc. dated as of September 17, 2015. ⁽⁹⁾
- 5.1 Opinion of Cooley LLP.
- 23.1 Consent of OUM & Co., LLP, Independent Registered Public Accounting Firm.
- 23.2 Consent of Ernst & Young, LLP, Independent Registered Public Accounting Firm.
- 23.3 Consent of Cooley LLP (included in Exhibit 5.1).
- 24.1 Power of Attorney. Reference is made to the signature page of this Form S-8.
- 99.1 2011 Equity Incentive Plan.⁽¹⁰⁾
- 99.2 Forms of Stock Option Grant Notice, Stock Option Exercise Notice and Stock Option Agreement under 2011 Equity Incentive Plan.⁽¹¹⁾
- 99.3 Form of Restricted Stock Unit Award Agreement under 2011 Equity Incentive Plan.⁽¹²⁾
- 99.4 2011 Employee Stock Purchase Plan.⁽¹³⁾

Incorporated
herein by
reference to
Exhibit 3.1 to
the
Registrant's
Current
Report on
(1) Form 8-K
(File No.
001-35068),
as filed with
the
Commission
on
February 18,
2011.
(2) Incorporated
herein by
reference to
Exhibit 3.4 to
the
Registrant's
Registration

Statement on
Form S-1
(File No.
333-170594),
as filed with
the
Commission
on January 7,
2011, as
amended.

Incorporated
herein by
reference to
Exhibit 4.2 to
the
Registrant's
Registration
Statement on

(3) Form S-1
(File No.
333-170594),
as filed with
the
Commission
on January
31, 2011, as
amended.

Incorporated
herein by
reference to
Exhibit 4.3 to
the
Registrant's
Registration
Statement on

(4) Form S-1
(File No.
333-170594),
as filed with
the
Commission
on November
12, 2010, as
amended.

- Incorporated herein
by reference to
Exhibit 4.5 to the
Registrant's Annual
Report on Form
(5) 10-K (File No.
001-35068), as
filed with the
Commission on
March 17, 2014.
Incorporated herein
by reference to
Exhibit 4.6 to the
Registrant's Annual
Report on Form
(6) 10-K (File No.
001-35068), as
filed with the
Commission on
March 17, 2014.
Incorporated herein
by reference to
Exhibit 4.8 to the
Registrant's Current
Report on Form
(7) 8-K (File No.
001-35068), as
filed with the
Commission on
May 30, 2012.
Incorporated herein
by reference to
Exhibit 4.7 to the
Registrant's
Quarterly Report
(8) on Form 10-Q (File
No. 001-35068), as
filed with the
Commission on
November 3, 2015.
(9) Incorporated herein
by reference to
Exhibit 4.8 to the
Registrant's
Quarterly Report
on Form 10-Q (File
No. 001-35068), as
filed with the

Commission on
November 3, 2015.
Incorporated herein
by reference to
Exhibit 99.3 to the
Registrant's
Registration

(10) Statement on Form
S-8 (File
No. 333-172409),
as filed with the
Commission on
February 24, 2011.
Incorporated herein
by reference to
Exhibit 10.5 to the
Registrant's Annual
Report on Form

(11) 10-K (File
No. 001-35068), as
filed with the
Commission on
March 30, 2011.
Incorporated herein
by reference to
Exhibit 10.6 to the
Registrant's Annual
Report on Form

(12) 10-K (File
No. 001-35068), as
filed with the
Commission on
March 30, 2011.
Incorporated herein
by reference to
Exhibit 99.6 to the
Registrant's
Registration

(13) Statement on Form
S-8 (File
No. 333-172409),
as filed with the
Commission on
February 24, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on this 7th day of March, 2016.

ACELRX PHARMACEUTICALS, INC.

By: /s/ HOWARD B. ROSEN
Howard B. Rosen
Interim Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints **HOWARD B. ROSEN** and **TIMOTHY E. MORRIS**, jointly and severally, as his true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ HOWARD B. ROSEN HOWARD B. ROSEN	Interim Chief Executive Officer and Director (Principal Executive Officer)	March 7, 2016

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form S-8

/s/ TIMOTHY E. MORRIS TIMOTHY E. MORRIS	Chief Financial Officer <i>(Principal Financial and Accounting Officer)</i>	March 7, 2016
/s/ ADRIAN ADAMS ADRIAN ADAMS	Chairman of the Board of Directors	March 7, 2016
/s/ PAMELA P. PALMER, M.D., PH.D. PAMELA P. PALMER, M.D., PH.D.	Director	March 7, 2016
/s/ MARK G. EDWARDS MARK G. EDWARDS	Director	March 7, 2016
/s/ STEPHEN J. HOFFMAN, PH.D., M.D. STEPHEN J. HOFFMAN, PH.D., M.D.	Director	March 7, 2016
/s/ RICHARD AFABLE, M.D. RICHARD AFABLE, M.D.	Director	March 7, 2016
/s/ MARK WAN MARK WAN	Director	March 7, 2016

EXHIBITS

Exhibit Number	Description
3.1	Amended and Restated Certificate of Incorporation of the Registrant. ⁽¹⁾
3.2	Amended and Restated Bylaws of the Registrant. ⁽²⁾
4.1	Reference is made to Exhibits 3.1 and 3.2.
4.2	Specimen Common Stock Certificate of the Registrant. ⁽³⁾
4.3	Second Amended and Restated Investor's Rights Agreement, among the Registrant and certain of its security holders, dated as of November 23, 2009. ⁽⁴⁾
4.4	Warrant to Purchase Common Stock of the Registrant, issued to Hercules Technology II, L.P., dated as of December 16, 2013. ⁽⁵⁾
4.5	Warrant to Purchase Common Stock of the Registrant, issued to Hercules Technology Growth Capital, Inc., dated as of December 16, 2013. ⁽⁶⁾
4.6	Form of Warrant issued to certain purchasers pursuant to the Securities Purchase Agreement dated May 29, 2012, between the Registrant and the purchasers identified therein. ⁽⁷⁾
4.7	Warrant Modification Agreement to Purchase Common Stock of the Registrant, issued to Hercules Technology II, L.P. dated as of September 17, 2015. ⁽⁸⁾
4.8	Warrant Modification Agreement to Purchase Common Stock of the Registrant, issued to Hercules Technology Growth Capital, Inc. dated as of September 17, 2015. ⁽⁹⁾
5.1	Opinion of Cooley LLP.
23.1	Consent of OUM & Co., LLP, Independent Registered Public Accounting Firm.
23.2	Consent of Ernst & Young, LLP, Independent Registered Public Accounting Firm.
23.3	Consent of Cooley LLP (included in Exhibit 5.1).
24.1	Power of Attorney. Reference is made to the signature page of this Form S-8.
99.1	2011 Equity Incentive Plan. ⁽¹⁰⁾
99.2	Forms of Stock Option Grant Notice, Stock Option Exercise Notice and Stock Option Agreement under 2011 Equity Incentive Plan. ⁽¹¹⁾

- 99.3 Form of Restricted Stock Unit Award Agreement under 2011 Equity Incentive Plan.⁽¹²⁾
- 99.4 2011 Employee Stock Purchase Plan.⁽¹³⁾

Incorporated
herein by
reference to
Exhibit 3.1 to the
Registrant's
(1) Current Report on
Form 8-K (File
No. 001-35068),
as filed with the
Commission on
February 18,
2011.

Incorporated
herein by
reference to
Exhibit 3.4 to the
Registrant's
Registration
(2) Statement on
Form S-1 (File
No. 333-170594),
as filed with the
Commission on
January 7, 2011,
as amended.

Incorporated
herein by
reference to
Exhibit 4.2 to the
Registrant's
Registration
(3) Statement on
Form S-1 (File
No. 333-170594),
as filed with the
Commission on
January 31, 2011,
as amended.

(4) Incorporated
herein by
reference to
Exhibit 4.3 to the
Registrant's
Registration
Statement on
Form S-1 (File

No. 333-170594),
as filed with the
Commission on
November 12,
2010, as amended.

Incorporated
herein by
reference to
Exhibit 4.5 to the
Registrant's

- (5) Annual Report on
Form 10-K (File
No. 001-35068),
as filed with the
Commission on
March 17, 2014.
Incorporated
herein by
reference to
Exhibit 4.6 to the
Registrant's

- (6) Annual Report on
Form 10-K (File
No. 001-35068),
as filed with the
Commission on
March 17, 2014.
Incorporated
herein by
reference to
Exhibit 4.8 to the
Registrant's

- (7) Current Report on
Form 8-K (File
No. 001-35068),
as filed with the
Commission on
May 30, 2012.
Incorporated
herein by
reference to
Exhibit 4.7 to the
Registrant's
Quarterly Report

- (8) on Form 10-Q
(File
No. 001-35068),
as filed with the
Commission on
November 3,
2015.

- Incorporated
herein by
reference to
Exhibit 4.8 to the
Registrant's
Quarterly Report
(9) on Form 10-Q
(File
No. 001-35068),
as filed with the
Commission on
November 3,
2015.
- Incorporated
herein by
reference to
Exhibit 99.3 to the
Registrant's
Registration
(10) Statement on
Form S-8 (File
No. 333-172409),
as filed with the
Commission on
February 24,
2011.
- Incorporated
herein by
reference to
Exhibit 10.5 to the
Registrant's
(11) Annual Report on
Form 10-K (File
No. 001-35068),
as filed with the
Commission on
March 30, 2011.
- Incorporated
herein by
reference to
Exhibit 10.6 to the
Registrant's
(12) Annual Report on
Form 10-K (File
No. 001-35068),
as filed with the
Commission on
March 30, 2011.
- (13) Incorporated
herein by
reference to

Exhibit 99.6 to the
Registrant's
Registration
Statement on
Form S-8 (File
No. 333-172409),
as filed with the
Commission on
February 24,
2011.